• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cassava Sciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    5/27/25 4:05:33 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAVA alert in real time by email
    sava20250523_8k.htm
    false 0001069530 0001069530 2025-05-23 2025-05-23

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     
    FORM 8-K
     

     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): May 23, 2025
     

     
    Cassava Sciences, Inc.
    (Exact name of registrant as specified in its charter)
     

     
    Delaware
    001-49105
    91-1911336
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification Number)
     
    6801 N Capital of Texas Highway, Building 1; Suite 300
    Austin, Texas 78731
    (Address of principal executive offices, including zip code)
     
    (512) 501-2444
    (Registrant’s telephone number, including area code)
     
     
    (Former name or former address, if changed since last report.)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
     
    ☐
    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
    ☐
    Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.001 par value
     
    SAVA
     
    Nasdaq Capital Market
     
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    As described in Item 5.07 below, on May 23, 2025, at the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) of Cassava Sciences, Inc. (the “Company”), the stockholders of the Company approved an amendment to the Company’s Non-employee Director Compensation Program (the “Amended Non-employee Director Compensation Program”). Under the Amended Non-employee Director Compensation Program, the compensation of our non-employee directors changed, effective May 23, 2025, as follows:
     
     
    ●
    The annual cash retainer would increase from $10,000 to $40,000.
     
     
    ●
    The director serving as Board Chair would receive an additional cash retainer of $30,000 annually.
     
     
    ●
    Stock option grants for committee service would be eliminated.
     
     
    ●
    Additional cash fees would be paid to the Chairs of the Audit, Compensation, and Nominating & Governance Committees of $15,000, $10,000, and $8,000 respectively.
     
     
    ●
    Additional cash fees would be paid to non-Chair members of the Audit, Compensation, and Nominating & Governance Committees of $7,500, $5,000, and $4,000 respectively.
     
     
    ●
    Annual equity awards to non-employee directors would increase from 10,000 to 26,500 stock options, vesting over one year.
     
     
    ●
    Initial equity awards to new non-employee directors would increase from 20,000 to 53,000 stock options, vesting over three years.
     
    For more information on the amendment, please see the related proposal in the Proxy Statement (as defined in Item 5.07 below).
     
    The foregoing description of the Amended Non-employee Director Compensation Program does not purport to be complete and is qualified in its entirety by reference to the full text of the amended Plan, a copy of which is attached as Exhibit 10.1 and is incorporated herein by reference.
     
    Item 5.07 Submission of Matters to a Vote of Security Holders.
     
    The 2025 Annual Meeting of the Company was held at approximately 10 a.m. Central Time on May 23, 2025, pursuant to the Notice of Annual Meeting of Stockholders dated April 14, 2025 and duly delivered to all Company stockholders of record as of April 3, 2025. Of the 48,307,896 shares of the Company’s common stock entitled to vote at the 2025 Annual Meeting, 24,553,054 shares, or approximately 51%, were represented at the 2025 Annual Meeting virtually or by proxy, constituting a quorum. At the 2025 Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 14, 2025 (the “Proxy Statement”). The following is a brief description of each matter voted on and the certified results, including the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter.
     
    Proposal One – Two (2) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes:
           
    Director
    For
    Withheld
    Broker Non-Vote
    Robert Anderson, Jr. 5,637,119 2,331,174 16,584,761
    Michael J. O’Donnell
    4,538,330
    3,429,963
    16,584,761
     
    Proposal Two – An amendment to the Company’s Non-employee Director Compensation Program was approved based upon the following votes:
                   
     
    For
     
    Against
     
    Abstain
     
    Broker Non -Vote
      6,660,591   1,209,200   98,502   16,584,761
     
    Proposal Three – An amendment to the Company’s Amended and Restated Certificate of Incorporation to reduce the Company's Board classification from three to two, which received an affirmative vote from approximately 91% of the votes cast, did not receive an affirmative vote of 66 2/3% of the outstanding common stock and was thus not approved based upon the following votes:
                   
     
    For
     
    Against
     
    Abstain
     
    Broker Non -Vote
      7,252,026   666,024   50,243   16,584,761
     
    Proposal Four – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025, was ratified based upon the following votes:
                 
     
    For
     
    Against
     
    Abstain
     
      23,212,403   1,116,152  
    224,499
     
     
    Proposal Five – The 2024 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes:
                   
     
    For
     
    Against
     
    Abstain
     
    Broker Non -Vote
      6,217,200   1,666,848   84,245   16,584,761
     
    9.01 Financial Statements and Exhibits
     
    Exhibit No.
     
    Description
    10.1   Cassava Sciences, Inc. Amended Non-employee Director Compensation Program
         
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
     
    CASSAVA SCIENCES, INC.
     
     
    a Delaware corporation
     
           
    Date: May 27, 2025
         
     
    By:
    /s/ ERIC J. SCHOEN
     
       
    Eric J. Schoen
     
       
    Chief Financial Officer
     
     
     
    Get the next $SAVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAVA

    DatePrice TargetRatingAnalyst
    11/26/2024Buy → Neutral
    H.C. Wainwright
    10/8/2024$116.00Neutral → Buy
    H.C. Wainwright
    7/1/2024Buy → Neutral
    H.C. Wainwright
    11/16/2022$44.00Buy → Neutral
    B. Riley Securities
    1/24/2022$108.00 → $72.00Buy
    B. Riley Securities
    7/20/2021$97.00 → $124.00Buy
    HC Wainwright & Co.
    7/15/2021$100.00Overweight → Neutral
    Cantor Fitzgerald
    7/7/2021$80.00 → $190.00Buy
    Maxim Group
    More analyst ratings

    $SAVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cassava Reports Q2 2025 Financials Results and Provides Business Update

    Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for c

    8/14/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

    Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development

    8/7/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

    Study in a TSC mouse model further demonstrates simufilam's anti-seizure activityStudy conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout modelFirst clinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) --  Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, today reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex (TSC)-related epilepsy. Most individuals with TSC experience

    8/4/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    SEC Filings

    View All

    SEC Form 10-Q filed by Cassava Sciences Inc.

    10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)

    8/14/25 8:15:27 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

    8/14/25 7:45:28 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

    8/4/25 7:45:28 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Scannon Patrick J Md Phd

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    7/16/25 4:04:20 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Anderson Robert Eugene Jr

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    5/27/25 4:26:31 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gravier Pierre

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    5/27/25 4:23:30 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cassava Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

    11/26/24 7:44:43 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00

    10/8/24 8:06:57 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

    7/1/24 7:48:24 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Financials

    Live finance-specific insights

    View All

    Cassava Sciences to Hold Corporate Update on November 25th

    AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.    Event Details:    Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast: https://lifescievents.com/event/cassava/    A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnolog

    11/24/24 8:01:09 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

    AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.   Event details:  Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy   A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

    10/31/24 8:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

    AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr   A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

    8/1/24 8:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Reports Q2 2025 Financials Results and Provides Business Update

    Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for c

    8/14/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

    Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development

    8/7/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

    As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bor

    5/1/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    2/13/24 5:01:04 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    2/1/24 4:00:47 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care